儿童临床试验市场－全球产业规模、份额、趋势、机会和预测：按阶段、研究设计、治疗领域、地区和竞争格局划分，2021-2031年

全球儿童临床试验市场预计将从 2025 年的 161.1 亿美元成长到 2031 年的 254.5 亿美元，复合年增长率为 7.92%。

该市场涵盖评估从婴儿期到18岁各年龄层治疗药物安全性和有效性的研究。推动这一市场扩张的关键因素包括：严格的监管要求强制要求对新药进行儿童评估，以及业界对罕见遗传疾病治疗日益增长的兴趣。根据美国製药商协会（PhRMA）预测，到2025年，将有超过560种针对儿童罕见疾病的新治疗方法正在开发平臺中，这一因素正持续推动整个产业的投资和研发投入。

儘管存在这些积极因素，但患者招募仍然是一项重大挑战，可能会减缓市场成长。符合条件的受试者数量有限，加上知情同意严格的伦理标准，常常导致研究週期延长和成本增加。因此，难以获得足够的患者以获得具有统计意义的可靠数据，这仍然是製药公司和合约研究组织（CRO）面临的持续性障碍，并可能阻碍儿童治疗药物的及时研发。

市场驱动因素

扩大的财政奖励和市场垄断条款正成为市场扩张的关键催化剂，尤其是透过诸如罕见儿童疾病优先审评券（PRV）计画等措施。这些监管机制正在将成功的儿童药物研发转化为宝贵的商业性资产，并鼓励研发人员将目标锁定在规模较小、盈利通常较低的患者群体。近年来，这些奖励的货币化潜力激增，催生了一个竞争激烈的二级市场，用于交易能够抵消高昂研发成本的优先审查券。 2025年3月，Biospace报道称，受大型製药公司对其旗舰产品加快审查的需求推动，这些优先审查券的交易价格在年初达到了1.5亿美元。这使得中小型生物技术公司能够获得即时资金并降低财务风险。

同时，罕见疾病和儿童罕见疾病研发投入的显着成长正在改变临床格局。业界正充分利用这些特殊认定所带来的高监管核准成功率。各公司越来越重视那些尚未充分满足的细分适应症，因为孤儿药疗法比标准疗法更容易获得核准。根据 Norm Bio（2025 年 11 月）预测，孤儿药的核准将达到 25-30%，远高于传统药物 10-12% 的成功率。美国製药商协会 (PhRMA) 的数据也反映了这个策略重点。 PhRMA 于 2025 年 10 月宣布，目前有超过 2,100 项由业界主导的儿童临床试验正在进行中，涉及 120 万名患者，这凸显了业界对复杂儿童疾病的重视。

市场挑战

病患招募困难造成了营运瓶颈，导致研究完成时间延长，研发成本增加，严重阻碍了全球儿童临床试验市场的成长。合格的儿童受试者短缺，加上严格的知情同意伦理要求，常常导致试验无法在计画时间内达到招募目标。当製药公司无法快速收集足够的数据时，整个开发平臺都会被延误，从而抑制未来对儿童特定适应症的投资，并限制整体市场规模。

近期行业调查结果也印证了这种营运效率低下的问题。根据临床研究专业人员协会 (ACRP) 的数据，到 2024 年，36% 的临床研究机构将把病患招募和留存列为一项主要的营运挑战。由于儿科患者群体规模较小且地理分布更为分散，因此儿童研究领域的问题更为严峻。由此，无法有效率地招募受试者会直接导致试验週期延长，增加申办者的财务风险，从而阻碍市场成长，并促使申办方在启动新的儿童研究时采取更为谨慎的态度。

市场趋势

人工智慧 (AI) 在精准队列识别方面的应用，正从根本上改变患者选择策略，使其从人工筛检转向对电子健康记录进行演算法分析。这项技术整合使申办方能够透过处理传统方法常常忽略的非结构化临床记录和遗传标记，快速识别合格的儿童受试者。透过从海量资料集中自动检测特定的纳入标准，製药研发公司可以减少因合格受试者短缺而导致的营运延误。美国国立卫生研究院 (NIH) 于 2024 年 6 月发布的题为《人工智慧在儿童临床试验中的应用》的报告指出，在儿童肿瘤试验中使用的 AI 演算法可将患者筛检工作量减少高达 90%，并显着加快合格候选者的识别速度。

同时，用于远距儿童监测的可穿戴设备的普及，透过最大限度地减少侵入性就诊的需求，提高了资料完整性和参与者保留率。这些非侵入性工具能够在儿童的自然环境中持续收集生理生物标记物，减轻家庭负担，并确保长期研究的持续参与。这种转变提高了所收集的真实世界数据的质量，并支持以患者为中心的、针对儿童人群需求的个人化方法。根据临床研究专业人员协会 (ACRP) 于 2024 年 10 月发表的题为「利用穿戴式数位健康技术增强临床试验」的报导，采用可穿戴技术的试验已实现了 70% 至 80% 的高患者依从率，证明了其在维持通讯协定依从性方面的有效性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球儿童临床试验市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 阶段（第一阶段、第二阶段、第三阶段、第四阶段）
  • 按研究设计（治疗性研究和观察性研究）
  • 依治疗领域（呼吸系统疾病、感染疾病、肿瘤、糖尿病及其他治疗领域）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美儿童临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲儿童临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区儿童临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲儿童临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲儿童临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球儿童临床试验市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Inc.
• Novartis AG
• Pfizer, Inc.
• Pharmaceutical Product Development, LLC
• Syneos Health Inc.
• Paidion Research, Inc.
• The Emmes Company, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pediatric Clinical Trials Market is projected to experience significant growth, rising from USD 16.11 Billion in 2025 to USD 25.45 Billion by 2031, reflecting a CAGR of 7.92%. This market encompasses research studies designed to assess the safety and efficacy of medical treatments specifically for the population aged from birth to 18 years. Primary factors driving this expansion include stringent regulatory mandates that require pediatric assessments for new medications and a heightened industry focus on treating rare genetic disorders. According to the Pharmaceutical Research and Manufacturers of America, there were over 560 novel therapies for rare diseases-which disproportionately impact children-in the development pipeline in 2025, a factor that continues to stimulate investment and research across the sector.

Despite these positive indicators, patient recruitment remains a formidable challenge that threatens to slow market growth. The restricted number of eligible participants, combined with rigorous ethical standards regarding informed consent, frequently results in prolonged timelines and escalating costs. Consequently, the difficulty in securing adequate enrollment to produce statistically robust data serves as a persistent obstacle for pharmaceutical companies and contract research organizations, potentially hindering the timely development of pediatric therapies.

Market Driver

The broadening of financial incentives and market exclusivity provisions serves as a major catalyst for market expansion, particularly through initiatives such as the Rare Pediatric Disease Priority Review Voucher (PRV) program. These regulatory mechanisms transform successful pediatric drug development into valuable commercial assets, encouraging developers to target smaller, often less profitable patient groups. The monetization potential of these incentives has surged recently, fostering a competitive secondary market for vouchers that helps subsidize high research costs. BioSpace reported in March 2025 that the trading price for these vouchers reached $150 million early in the year, driven by demand from major pharmaceutical firms seeking expedited review for flagship products, thereby providing immediate capital to smaller biotech firms and reducing financial risks.

Simultaneously, a significant increase in R&D for rare and orphan pediatric disorders is reshaping the clinical landscape, as the industry leverages the higher regulatory success rates associated with these special designations. Companies are increasingly prioritizing niche indications with high unmet needs, utilizing the fact that orphan-designated therapies often navigate approval processes more efficiently than standard treatments. According to Nome Bio in November 2025, orphan-designated products are achieving approval rates of 25-30%, significantly outperforming the 10-12% success rate of conventional drugs. This strategic focus is reflected in data from the Pharmaceutical Research and Manufacturers of America (PhRMA), which noted in October 2025 that over 2,100 industry-sponsored pediatric trials involving 1.2 million patients are currently underway, highlighting the sector's commitment to complex pediatric conditions.

Market Challenge

Difficulties regarding patient recruitment significantly hinder the growth of the Global Pediatric Clinical Trials Market by causing operational bottlenecks that delay study completion and increase development costs. The scarcity of eligible pediatric subjects, exacerbated by strict ethical requirements for informed consent, often leads to trials failing to meet enrollment targets within planned schedules. When pharmaceutical companies are unable to gather sufficient data promptly, the entire development pipeline slows, which discourages future investment in pediatric-specific indications and limits overall market volume.

This operational inefficiency is supported by recent industry findings. Data from the Association of Clinical Research Professionals indicates that in 2024, 36% of clinical research sites cited patient recruitment and retention as their primary operational challenge. This issue is even more acute in pediatric research, where patient pools are naturally smaller and more geographically dispersed than in adult populations. Consequently, the inability to efficiently enroll participants directly impedes market growth by extending trial durations and increasing financial risks for sponsors, resulting in a more cautious approach toward initiating new pediatric studies.

Market Trends

The adoption of Artificial Intelligence for Precise Cohort Identification is fundamentally transforming patient selection strategies by moving from manual screening to the algorithmic analysis of electronic health records. This technological integration enables sponsors to swiftly identify eligible pediatric participants by processing unstructured clinical notes and genetic markers that traditional methods might miss. By automating the detection of specific inclusion criteria across vast datasets, pharmaceutical developers can alleviate operational delays caused by the shortage of eligible subjects. A June 2024 report by the National Institutes of Health, titled 'Applying Artificial Intelligence in Pediatric Clinical Trials,' noted that AI algorithms used in pediatric oncology trials reduced the patient screening workload by up to 90%, significantly accelerating the identification of suitable candidates.

In parallel, the increasing use of Wearable Devices for Remote Pediatric Monitoring is enhancing data integrity and participant retention by minimizing the need for intrusive on-site visits. These non-invasive tools allow for the continuous collection of physiological biomarkers in the child's natural environment, thereby reducing the logistical burden on families and ensuring consistent engagement during long-term studies. This shift improves the quality of real-world evidence gathered and supports a patient-centric approach aligned with the needs of pediatric populations. According to the Association of Clinical Research Professionals in October 2024, in the 'Enhancing Clinical Trials with Wearable Digital Health Technologies' article, trials incorporating wearable technologies achieved high patient adherence rates between 70% and 80%, demonstrating their effectiveness in maintaining protocol compliance.

Key Market Players

• Bristol-Myers Squibb Company
• Charles River Laboratories International Inc.
• Covance Inc.
• GlaxoSmithKline plc
• ICON plc
• IQVIA Inc.
• Novartis AG
• Pfizer, Inc.
• Pharmaceutical Product Development, LLC
• Syneos Health Inc.
• Paidion Research, Inc.
• The Emmes Company, LLC

Report Scope

In this report, the Global Pediatric Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Clinical Trials Market, By Phase

• Phase I
• Phase II
• Phase III
• and Phase IV

Pediatric Clinical Trials Market, By Study Design

• Treatment Studies and Observational Studies

Pediatric Clinical Trials Market, By Therapeutic Area

• Respiratory Diseases
• Infectious Diseases
• Oncology
• Diabetes
• and Other Therapeutic Areas

Pediatric Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Clinical Trials Market.

Available Customizations:

Global Pediatric Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV)
  • 5.2.2. By Study Design (Treatment Studies and Observational Studies)
  • 5.2.3. By Therapeutic Area (Respiratory Diseases, Infectious Diseases, Oncology, Diabetes, and Other Therapeutic Areas)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pediatric Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Therapeutic Area
  • 6.3.2. Canada Pediatric Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Therapeutic Area
  • 6.3.3. Mexico Pediatric Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Therapeutic Area

7. Europe Pediatric Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Therapeutic Area
  • 7.3.2. France Pediatric Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Therapeutic Area
  • 7.3.3. United Kingdom Pediatric Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Therapeutic Area
  • 7.3.4. Italy Pediatric Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Therapeutic Area
  • 7.3.5. Spain Pediatric Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Therapeutic Area

8. Asia Pacific Pediatric Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pediatric Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Therapeutic Area
  • 8.3.2. India Pediatric Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Therapeutic Area
  • 8.3.3. Japan Pediatric Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Therapeutic Area
  • 8.3.4. South Korea Pediatric Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Study Design
      • 8.3.4.2.3. By Therapeutic Area
  • 8.3.5. Australia Pediatric Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Study Design
      • 8.3.5.2.3. By Therapeutic Area

9. Middle East & Africa Pediatric Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pediatric Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Therapeutic Area
  • 9.3.2. UAE Pediatric Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Therapeutic Area
  • 9.3.3. South Africa Pediatric Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Therapeutic Area

10. South America Pediatric Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pediatric Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Therapeutic Area
  • 10.3.2. Colombia Pediatric Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Therapeutic Area
  • 10.3.3. Argentina Pediatric Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pediatric Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Charles River Laboratories International Inc.
• 15.3. Covance Inc.
• 15.4. GlaxoSmithKline plc
• 15.5. ICON plc
• 15.6. IQVIA Inc.
• 15.7. Novartis AG
• 15.8. Pfizer, Inc.
• 15.9. Pharmaceutical Product Development, LLC
• 15.10. Syneos Health Inc.
• 15.11. Paidion Research, Inc.
• 15.12. The Emmes Company, LLC

16. Strategic Recommendations

17. About Us & Disclaimer